Get the Stockscreener App
8.91
3.97%
0.34
After Hours:
9.05
0.14
+1.57%
Immix Biopharma Inc stock is traded at $8.91, with a volume of 768.67K.
It is up +3.97% in the last 24 hours and up +1.83% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.57
Open:
$9.14
24h Volume:
768.67K
Relative Volume:
0.88
Market Cap:
$471.83M
Revenue:
-
Net Income/Loss:
$-23.56M
P/E Ratio:
-11.33
EPS:
-0.7861
Net Cash Flow:
$-15.45M
1W Performance:
-5.81%
1M Performance:
+1.83%
6M Performance:
+336.76%
1Y Performance:
+381.62%
1-Day Range:
$8.72
$9.35
1-Week Range:
$8.25
$10.09
52-Week Range:
$1.34
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.91 | 453.83M | 0 | -23.56M | -15.45M | -0.7861 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Millennium Management LLC Acquires Significant Stake in Immix Biopharma Inc - GuruFocus
Immix Biopharma, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma amends at-the-market offering agreement for up to $100 million - Investing.com
Immix Biopharma Amends ATM Offering to Raise Capital - TipRanks
Immix Biopharma Updates $100 Million ATM Equity Offering With Citizens JMP Securities - TradingView
Immix Biopharma 2025 10-K: Net loss $29.44M, EPS $(0.89) - TradingView
Immix Biopharma (NASDAQ: IMMX) amends $100M at-the-market stock sale - Stock Titan
Immix Biopharma (IMMX) plans $100M ATM with Citizens JMP Securities - Stock Titan
Immix Biopharma (NASDAQ: IMMX) advances NXC-201 with designations and $100M offering - Stock Titan
Immix stock wins Morgan Stanley bullish view (IMMX:NASDAQ) - Seeking Alpha
Immix Biopharma (NASDAQ:IMMX) Now Covered by Analysts at Morgan Stanley - MarketBeat
Morgan Stanley initiates Immix Biopharma stock with overweight rating By Investing.com - Investing.com Canada
Immix Biopharma signed Amendment No. 1 to its ATM (At-the-Market) Offering Agreement on March 25, 2026. - Bitget
Targets Report: Does Immix Biopharma Inc have consistent dividend growth2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Artificial Intelligence Technology Solutions, Inc.: AITX's RAD and Immix Announce Integration of RAD Devices into Immix Platform - FinanzNachrichten.de
If You Invested $1,000 in Immix Biopharma Inc (IMMX) - Stock Titan
Market Wrap: Is Immix Biopharma Inc stock a buy or sell2026 Spike Watch & Daily Price Action Insights - baoquankhu1.vn
Millennium Group and Israel Englander disclose 2.81M IMMX stake (IMMX) - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Shares Down 8.9%Should You Sell? - MarketBeat
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3%What's Next? - MarketBeat
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 13.4% - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Hits New 12-Month HighHere's Why - MarketBeat
Immix Biopharma (IMMX) to Release Earnings on Monday - MarketBeat
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch - MSN
Immix Biopharma (NASDAQ:IMMX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00 - Defense World
IMMX Technical Analysis & ETF Price Forecast - Intellectia AI
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Citizens initiates Immix Biopharma stock coverage with outperform rating By Investing.com - Investing.com Canada
Citizens initiates Immix Biopharma stock coverage with outperform rating - Investing.com South Africa
Aug Wrap: Does Immix Biopharma Inc have consistent dividend growthMarket Growth Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Macro Review: Is Immix Biopharma Inc stock a good pick for beginners2026 Market Overview & Growth Focused Entry Point Reports - baoquankhu1.vn
Why Immix Biopharma Inc. stock could rally in 20262026 Big Picture & Reliable Trade Execution Plans - Naître et grandir
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
33,035,515 Common Stock of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Is Immix Biopharma Inc. stock a top momentum play2025 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Trade Recap: Is Immix Biopharma Inc in a bullish channel2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Insider Buy: What dividend growth rate does Immix Biopharma Inc offerTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
IMMX Should I Buy - Intellectia AI
IMMX Technical Analysis & Stock Price Forecast - Intellectia AI
IMMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment manager Saturn V holds 6.97% of Immix Biopharma (IMMX) - Stock Titan
Immix Biopharma (IMMX) sees Janus Henderson report 7.4% stake - Stock Titan
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance
Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho - MarketBeat
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):